Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg produces significant weight loss in adults with overweight or obesity regardless of baseline characteristics such as age, race, or baseline BMI, although females and those with lower baseline body weight experience greater magnitude of loss.
Semaglutide 2.4mg weekly, combined with lifestyle changes, is effective for weight loss across diverse demographics. While women and those starting at a lower weight may lose more, men and those with higher starting weights still achieve significant, clinically meaningful weight reduction. Do not skip treatment based on demographics.
In STEP 1, weight loss with once-weekly s.c. semaglutide 2.4 mg was seen in all subgroups evaluated, and was generally not influenced by baseline characteristics. The exception was sex and baseline body weight; female sex and a low baseline body weight were associated with a greater response to semaglutide.
Why this rating
Phase 3 randomized, double-blind, placebo-controlled trial with a large sample size (n=1,961).
Source
Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
Robert F. Kushner et al. · Journal of the Endocrine Society · 2021
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →